MUMBAI: Mylan Pharmaceuticals launched HepBest 25 mg (tenofovir alafenamide, TAF), Once a day tablet for the treatment of chronic hepatitis B in adults. HepBest (TAF) is the first tablet in 8 years to be approved for the management of chronic hepatitis B in India, says a Organisation statement.
Hetero and Natco are also in the process of launching the drug, industry experts say. The drug TAF demonstrates comparable efficacy, with an enhanced renal and bone safety profile as compared to earlier formulation of tenofovir (tenofovir disoproxil fumarate)
According to World Health Organization (WHO) estimates, over 2 billion people worldwide are contaminated with hepatitis B virus (HBV), of which over 240 million have chronic liver infection.
The cost of therapy for ‘HepBest’ will be Rs 1900 per month, the tablet is available in pack of 30s. Going forward with economies of scale, the prices are expected to come down like it has been the case for Tenofovir and Entecavir, a company spokesperson said.
Related: The Dietary Plan for a Healthy Heart
These patients are in danger of creating genuine disease and demise, to a great extent coming about because of liver cirrhosis and liver tumor. TAF exhibits similar viability with an upgraded renal and bone security profile when contrasted with the before plan of (tenofovir disoproxil fumarate). TAF additionally has more prominent plasma security, which guarantees proficient medication conveyance to the site of activity.
Commenting on the launch, Rakesh Bamzai, president, India and emerging markets said, “India has an estimated 40 million HBV conveyor, of which 15% to 25% could go on to suffer from cirrhosis and liver cancer. Mylan Pharmaceuticals continues to be in the forefront of introducing new treatment regimens for the management of hepatitis in India”.
In 2014, Mylan Pharmaceuticals signed an agreement with Gilead to enhance access to TAF-based HIV treatments in developing countries. As part of the licensing agreement, on US Food and Drug Administration (FDA) approval, Mylan Pharmaceuticals received a technology transfer from Gilead, enabling it to manufacture low-cost versions of TAF.
For more india latest news and updates stay connected here..